Indian Minister Defends Price Controls In Face Of Industry Opposition
This article was originally published in PharmAsia News
A minister of the Indian government defends the country's price-control policy as not as punitive on drug makers as they claim. Chemicals and Fertiliser Minister Ram Vilas Paswan denied claims of drug makers, saying they earn enough that they are not adversely affected by price controls. The industry has threatened to stop making certain drugs if controlled profit margins on bulk drugs, lowered in March, are not moved back up. Drug makers note the increased cost of raw materials they use to make their drugs and increased fuel and other costs. (Click here for more
You may also be interested in...
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.
A PwC analysis finds biopharma aggregate deal value declined 87% during the first half compared to the second half of 2018; deal volume dropped 17%. The pandemic was a cause, but not the only factor.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.